

CURRICULUM VITAE

NAME: James "Jim" Caldwell. Oates

OFFICE ADDRESS: Division of Rheumatology & Immunology
96 Jonathan Lucas Street, Suite 912
P.O. Box 250637
Charleston, SC 29425

EDUCATION:

<u>Years</u>	<u>Training</u>	<u>Location</u>
1982-1986	B.S. in Chemistry	Bates College
1986-1991	M.D.	Johns Hopkins Univ. School of Medicine
1991-1992	Internship	Duke Univ. Medical Ctr.
1992-1994	Residency (Internal Med.)	Duke Univ. Medical Ctr.
1994	3 month Infectious Disease rotation.	Muhimbili Medical Center Dar es Salaam, Tanzania
1994-1996	Fellowship (Rheumatology)	Duke Univ. Medical Ctr.
1996-1997	Fellowship (Rheumatology)	MUSC

SPECIALTY CERTIFICATION: Board Certified in Internal Medicine, 1995, 2005
Board Certified in Rheumatology, 1997, 2007

LICENSURE: South Carolina 18836, 1996

FACULTY APPOINTMENTS:

<u>Years</u>	<u>Rank</u>	<u>Department</u>	<u>Institution</u>
1997 - 1998	Instructor of Medicine	Medicine	MUSC
1997 - 2001	Associate Investigator	Medicine/Research	VAMC
1998 - 2006	Assistant Professor of Medicine	Medicine	MUSC
July 2006 - present	Associate Professor of Medicine	Medicine	MUSC
2007 – present	Chief, Rheumatology Section	Medical Service	VAMC
2007 – present	Associate Director	GCRC	MUSC

AWARDS, HONORS MEMBERSHIP IN HONORARY SOCIETIES:

Dana Scholar, Bates College, Lewiston, ME

Phi Beta Kappa, Bates College, Lewiston, ME

Four Schools Physician Scientist Training Program Scholar, Johns Hopkins University School of Medicine, Duke University Medical Center, 1989-1996

Senior Rheumatology Scholar Award, American College of Rheumatology, 1997

Associate Investigator Award, Department of Veterans Affairs, 1997-2000.

Merck Young Investigator Award, 2001.

Advanced Research Career Development Award, Department of Veterans Affairs, received but declined.

Arthritis Investigator Award, Arthritis Foundation, 2001-2004.

Research Education Foundation/European League Against Rheumatism International Exchange Award, 2003.

Health Sciences Foundation Developing Scholar Award, MUSC, 2003.

"America's Top Physicians" Consumers' Research Council of America, 2007.

"Best Doctors in America", Best Doctors, Inc., 2007

ADMINISTRATIVE SERVICE:

1999 – 2004 Member of the Department of Medicine Compliance Committee

1999 – 2004 Member of the Electronic Medical Record (EMERALD) Committee

2001 – 2003 Member of the VA Pharmacy and Therapeutics Committee

2003- 2004. Member of the Clinical Information Management Council (CIMC)

2002 – 2005 Member, University Research Committee, peer review for MUSC-funded research.

2004 – 2005 Member of Academic/Research Information Technology Group

2005 – present Member of GCRC Advisory and Operations Committees

2006 - present Member Department Web Site Development Committee

2007 – present Chief, Rheumatology Section, Ralph H. Johnson VAMC
2007 – present Associate Director of the General Clinical Research Center, MUSC
2008 – present Member of Implementation Working Committee to the Vice Provost for electronic IRB, MUSC

NATIONAL AND REGIONAL COMMITTEES:

2000 – 2004. American College of Rheumatology RSAP subcommittee.
2001 – 2006. Councilor, National Council of American Federation for Medical Research
2001 - 2004. Secretary/Treasurer of Southern Region of the Amer. Federation for Medical Research.
2004 – 2005. Chair-elect of Southern Region of the American Federation for Medical Research
2005 – 2006 Chair of Southern Region of the American Federation for Medical Research
2005 – 2006 Councilor, Southern Society for Clinical Investigation.
2005 – 2006 Chair, Joint Council, Southern Regional Meeting
2006- 2007 Secretary-Treasurer-elect Southern Society for Clinical Investigation
2007 – present Secretary-Treasurer Southern Society for Clinical Investigation
2006 – 2007 President-elect American Federation for Medical Research
2007 – present President, American Federation for Medical Research
2007 – present Member of Steering Committee - Association of Professors of Medicine Physician-Scientist Initiative
2007 – present Member of Legislative Action Committee – Clinical Research Forum

STUDY SECTIONS:

PRMRP, peer-reviewer for the medical research program in the Department of Defense based on expertise.

Veterans Administration Merit Review Immunology A study section

Arthritis Foundation – Clinical Immunology

University Research Committee, peer review for MUSC-funded research.

Lupus Foundation of America

JOURNAL PEER REVIEW/EDITORIAL BOARDS:

Journal of Investigative Medicine, Associate Editor

American Journal of Medical Sciences, Member of Editorial Board

Canadian Institutes of Health Research, ad hoc reviewer based on expertise

Journal of Rheumatology, ad hoc reviewer

Arthritis and Rheumatism, ad hoc reviewer

American Journal of Physiology - Renal Physiology, ad hoc reviewer

Arthritis Research & Therapy, ad hoc reviewer

American Journal of Medicine, ad hoc reviewer

Journal of Pharmacology and Experimental Therapeutics, ad hoc reviewer

Immunobiology, ad hoc reviewer

American Federation for Medical Research, Southern Regional Meeting, 2001-2006 ad hoc reviewer.

American Federation for Medical Research, National Council reviewer for Henry Christian, Outstanding Investigator and Junior Investigator Award, 2004-present.

EXTRAMURAL GRANTS:

VA Career Development Award, 1997-2000.

VA Advanced Research Career Development Award, received but declined.

VA Merit Review Award, Urine protein markers of disease in lupus nephritis, PI, active.

NIH RO1 The role of nitric oxide in SLE co-PI, active.

NIH RO1 The role of PPAR γ and its agonists in SLE, co-I, active.

NIH R21 Urine protein markers of disease in lupus nephritis, PI, completed

NIH K08 The role of nitric oxide and eicosanoids in SLE, PI, completed.

Lupus Foundation of America, Biomarkers of Atherosclerosis in SLE, complete.

Arthritis Foundation Arthritis Investigator Award, PI, completed.

Alliance for Lupus Research. The role of sphingosine kinase in systemic lupus erythematosus. PI, active.

Biogen – efficacy, safety, and pharmacokinetics of BG9588, PI, closed.

Pharmacia – the role of COX2 in murine lupus nephritis, PI, completed.

Genentech – Efficacy and safety of rituximab in patients with moderate to severe SLE, PI, active.

Aspreva – Aspreva lupus management study, co-PI, active.

Genentech – Efficacy and safety of rituximab in patients with active lupus nephritis, co-pI, active.
Bristol-Myers Squibb – Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination with Prednisone, co-pI, active.
Schering Plough - Rising Single- and Multiple-Dose Safety, Tolerance, and Pharmacokinetic Study of a Monoclonal Antibody Against IL-10 (SCH 708980) in Systemic Lupus Erythematosus (SLE) Patients, PI, active.

Clinical Research Trials:

PI – Phase I trial of infusion monoclonal antibody for systemic lupus erythematosus, closed.
PI – Phase III trial of infusion monoclonal antibody for active systemic lupus erythematosus. Seven subjects enrolled. closed.
PI – Phase III trial of infusion monoclonal antibody for active systemic lupus erythematosus. Enrollment to begin in April 2008.
Co-investigator – Phase III trial of infusion monoclonal antibody for active lupus nephritis. Enrollment to begin in April 2008.
Co-investigator – Phase III trial of infusion monoclonal antibody for active lupus nephritis. closed.
Co-investigator Phase III trial of infusion therapy for active systemic lupus erythematosus.. Active.
Co-investigator – Phase III trial of three conventional therapies for lupus nephritis. closed.
PI – Phase I/II trial of infusion monoclonal antibody for systemic lupus erythematosus. Study terminated for safety reasons prior to enrollment at our site. Closed.
Co-investigator – Phase III trial comparing two immunosuppressive medications as inducers of remission in lupus nephritis. 11 subjects enrolled Closed.
Co-investigator – Phase III trial of infused toleragen to reduce renal flares in subjects with lupus nephritis in remission. Nine subjects enrolled. Closed.
Co-investigator – Phase III trial of oral metalloproteinase inhibitor for active arthritis in systemic lupus erythematosus. Six subjects enrolled. Closed.
Co-investigator – Phase I trial of infused drug in systemic lupus erythematosus to determine pharmacokinetics. One subject enrolled. Closed.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:

American Association for the Advancement of Science
American College of Rheumatology
American Federation for Medical Research
Nitric Oxide Society
Free Radical Biology and Medicine
Southern Society for Clinical Investigation

TEACHING RESPONSIBILITIES:

1997-present. Teaching attending - 2 mos/yr - responsible for formal teaching exercises involving medical students, fellows & residents, MUSC. Teaching usually revolves around a patient that the housestaff or students have seen during the rheumatology rotation.
1997-present. Consult attending - 2 mos/yr - informal teaching to medical students, residents & fellows during consult rounds, MUSC. This involves bedside teaching and discussion of the literature regarding individual cases.
1997 – 2004. Internal Medicine ward attending - 1 mo/yr - responsible for formal & informal teaching of medical students & residents during teaching/ward rounds at the VAMC, Charleston, SC.
1998 – 2006. Physical Diagnosis II – several sessions in the second semester – responsible for formal and bedside instruction and grading of medical students in the Physical Diagnosis course.
1999 – present. Invited lectures annually on “pediatric arthritis” to the graduate nursing program. 2 hours.
2000 – 2001. Parallel curriculum clinical evaluation – responsible for observing a Parallel Curriculum student performance of history and physical examination on an actor/patient and later a detailed presentation of anatomy, physiology, pharmacology, natural history of disease, cell biology, biochemistry as they relate to the mock patient’s problem. During these interactive sessions, I provide feedback, evaluations, and further instruction as needed.
2001 – 2001. Third Year Clinical Preceptorship – weekly informal sessions involving third year medical students whereby students present cases or clinical scenarios about which they would like further instruction – responsible for clinical instruction (mostly Socratic method) and feedback to students.

- 2001 – present. VA teaching rounds. Bedside and case-oriented rheumatology-related teaching to the VA ward teams to supplement their formal curriculum. One hour every 1-2 weeks.
- 2001 – present. Formal lecture to the ophthalmology residents on ocular manifestations of rheumatic diseases. One hour annually.
- 2002 – 2003. Physical Diagnosis I – formal lecture regarding normal physical examination. One hour annually.
- 2003 – 2005. – lecture to dermatology residents on immunopathogenesis of SLE. One hour.
- 2001, 2006 – Lipid mediators of inflammation course, lecture and seminar relating to the role reactive intermediates and eicosanoids in lupus nephritis.
- 2007 Physical Diagnosis I – responsible for leading several sessions in the second semester on the normal physical exam and grading exams on actors.
- 2008 VA ward rounds – bedside patient care and case-based teaching to ward resident, interns, and medical students.

RESEARCH INTERESTS:

- Biomarkers of atherosclerosis in SLE – A study to determine the effectiveness of serum 3-chlorotyrosine, 3-nitrotyrosine, ortho-tyrosine, and meta-tyrosine as biomarkers of cardiovascular disease in SLE. These markers will be compared to traditional risk factors of atherosclerosis with carotid plaque area as the endpoint.
- Biomarkers of lupus nephritis– we are collaborating with Biometry and Epidemiology and the Nephrology Proteomics core to develop urine biomarkers of lupus nephritis using proteomic techniques and artificial neural network model generation. We are currently conducting a cross sectional and longitudinal study using proteomic techniques to determine if differential protein expression can predict ISN/RPS class and NIH activity/chronicity, and ultimately response to therapy in lupus nephritis.
- The role of nitric oxide in systemic lupus erythematosus. A study of how reactive intermediates lead to pathology in lupus and how markers of systemic reactive intermediate production can serve as markers of disease activity and response to therapy.
- The role of sphingosine kinase in systemic lupus erythematosus. A study of the effectiveness of sphingosine kinase inhibition in murine lupus nephritis and the mechanisms of action leading to this effectiveness.
- Our laboratory specializes in reactive oxygen and nitrogen surrogate measures using chemiluminescence detection of nitrate and nitrite, HPLC with electrochemical detection of modified tyrosines, and gas chromatography-mass spectrometry measures of isoprostane and cyclooxygenase-derived thromboxane. The latter efforts are in collaboration with Kennerly Patrick, PhD in the Department of Pharmaceutical Sciences.

BIBLIOGRAPHY:

Journal Articles:

1. Woosley RL, Roden DM, Dai GH, Wang T, Altenbern D, **Oates J**, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. *Clin. Pharmacol. Ther.* 1986;39(3):282-7.
2. **Oates JC**, Ruiz P, Alexander A, Phippen AM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. *Clin. Immunol. Immunopathol.* 1997;83(1):86-92.
3. Gilkeson G, Cannon C, **Oates J**, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. *J. Rheumatol.* 1999;26(2):318-24.
4. **Oates JC**, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. *Proc. Assoc. Am. Physicians* 1999;111(6):611-621.
5. Crofford LJ, **Oates JC**, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors - A report of four cases. *Arthritis Rheum.* 2000;43(8):1891-1896.
6. Reilly CM, **Oates JC**, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. *J. Immunol.* 2000;164(3):1498-504.
7. Reilly CM, **Oates JC**, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. *Clinical Immunology* 2001;98(3):337-345.

8. **Oates, JC**, Reilly, CM, Crosby, MB, Gilkeson, GS. PPAR γ agonists –Potential use for treating chronic inflammatory diseases. *Arthritis Rheum.* 46(3):598-605,2002.
9. **Oates JC**, Gilkeson GS. Mediators of injury in lupus nephritis. *Curr Opin Rheumatol* 14:498-503.2002.
10. **Oates JC**, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. *J. Rheumatol.* 2003;30(1):60-7.
11. Afrin LB, Oates JC, Boyd CK, Daniels MS. Leveraging of open EMR architecture for clinical trial accrual. *AMIA Annu Symp Proc* 2003:16-20.
12. **Oates JC**, Gilkeson GS. Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. *J Investig Med* 2004;52(1): 61-72.
13. Tourkina E, Gooz P, **Oates JC**, Ludwicka-Bradley A, Silver RM, Hoffman S. Curcumin-Induced Apoptosis in Scleroderma Lung Fibroblasts: Role of Protein Kinase C{epsilon}. *Am. J. Respir. Cell Mol. Biol.* 2004;31(1):28-35.
14. Bogatkevich GS, Gustilo E, **Oates JC**, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. *Am J Physiol Lung Cell Mol Physiol* 2005;288(1):L190-201.
15. **Oates JC**, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM. Prediction of urinary protein markers in lupus nephritis. *Kidney Int* 2005;68(6):2588-92.
16. Njoku CJ, Patrick KS, Ruiz Jr P, **Oates JC**. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. *J Investig Med* 2005;53(7):347-52.
17. Donovan JL, DeVane CL, Chavin KD, **Oates JC**, Njoku C, Patrick KS, Fiorini RN, Markowitz JS. Oral administration of a decaffeinated green tea (*Camellia sinensis*) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation. *J Pharm Pharmacol* 2005;57(10):1365-9.
18. Yu L, Wang J, O'Dell JR, **Oates J**, Arend WP, Eisenbarth GS. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. *J Rheumatol* 2007;34:734-9.
19. Varghese SA, Powell TB, Budisavljevic MN, **Oates JC**, Raymond JR, Almeida JS, et al. Urine biomarkers predict the cause of glomerular disease. *J Am Soc Nephrol* 2007;18:913-22.
20. **Oates JC**, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS. Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. *Arthritis Rheum.* 2007 Nov;56(11):3738-47.
21. Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, **Oates J**, Gilkeson G. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. *The Journal of rheumatology.* 2007 Oct;34(10):2028-34.
22. **Oates JC**, Shaftman SR, Self SE, Gilkeson GS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. *Arthritis Rheum.* 2008 Jan;58(1):263-72.
23. Evans JT, Shepard MM, **Oates JC**, Self SE, Reuben A. Rituximab-responsive Cryoglobulinemic Glomerulonephritis in a Patient With Autoimmune Hepatitis. *J Clin Gastroentrol.* 2008. Epub ahead of print April 23, 2008. Manuscript ID MS6172R2.
24. Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, **Oates JC**. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. *J Investig Med* 2008 Oct;56(7):911-9.
25. **Oates JC**, Shaftman SR, Bird-Lake K, Gilkeson GS, Self SE. Predictors of Outcome Among Clinical and Biopsy Variables in Lupus Nephritis. In preparation.

Invited Chapters/reviews/editorials:

1. **Oates JC**, Gilkeson GS. Mediators of inflammation, tissue destruction, and repair. Arachidonic acid derivatives, reactive oxygen species, and other mediators. In: Klippel JH, Weyand CM, Wortmann RL, editors. *Primer on the Rheumatic Diseases.* 12 ed. Atlanta, GA: Arthritis Foundation; 2001. p. 81-88.
2. **Oates JC**, Gilkeson GS. Nitric oxide and related compounds. In: Koopman WJ, Moreland LW, editors. *Arthritis and Allied Conditions A Textbook of Rheumatology.* 15th ed. Baltimore: Williams & Wilkins; 2004. p. 541-555.

3. **Oates JC**, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. *Clin Immunol.* 2006;121(3):243-50.
4. **Oates J**. Renal biopsy at the onset of clinical lupus nephritis: can it yield useful information? *J Rheumatol* 2007;34:256-8.
5. **Oates JC**, Gilkeson GS. Nitric Oxide in SLE. In: Tsokos GC, Gordon C, Smolen JS, editors. *Systemic lupus erythematosus : a companion to Rheumatology* 1st ed. Philadelphia: Mosby Elsevier; 2007. p. xv, 586 p.
6. Gilkeson GS, **Oates JC**. (2009) *Reactive Intermediates, Inflammation and Epigenetics in Lupus. The Epigenetics of Autoimmune Diseases*: in press.
7. Andrews N, Burris JE, Cech TR, Coller BS, Crowley Jr. WF, Gallin EK, Kelner KL, Kirch DG, Leshner AI, Morris CD, Nguyen F, **Oates J**, Sung NS. Translational Careers. *Science*. [Editorial]. 2008 27 March;323:1646.

Abstracts:

1. **Oates, JC**, Gilkeson GS. Effect of nitric oxide on apoptosis of peripheral lymphocytes in MRL-*lpr* mice. *Keystone Symposium, 1996; Lymphocyte Activation E4:1038.*
2. **Oates JC**, Alexander A, Gilkeson G. Effect of nitric oxide production on murine SLE. *Arthritis Rheum* 39(suppl.):310, 1996.
3. **Oates JC**, Gilkeson G. Increased apoptosis of MRL/*lpr* splenocytes is secondary to elevated nitric oxide production. *Arthritis Rheum* 40(9) (suppl.), 1997.
4. **Oates JC**, Reilly CM, Christensen EF, Gilkeson GS. Nitric oxide is increased during lupus disease activity. *Arthritis Rheum* 41(9)(suppl.):229, 1998.
5. Legerton CW, Christensen EF, Pandey J, Nietert PJ, Sutherland SE, Silver RM, and **Oates JC**. Nitric oxide levels in systemic sclerosis: correlation with clinical parameters. *Arthritis Rheum* 41(9)(suppl.):1749, 1998.
6. **Oates JC**, Christensen E.F., Halushka P.V., and Gilkeson G.S. Administration of the selective COX-2 inhibitor SC-236 reduces renal thromboxane production and spares renal function. *Arthritis Rheum.* 42(suppl): 1999.
7. Hill, B.S., Milano, I.D., **Oates, JC**, and Gilkeson, G.S. Nitric Oxide Synthase-2 (NOS2) Promoter Polymorphism in African American Subjects Associates with Systemic Lupus Erythematosus (SLE). *Arthritis Rheum.* 42(suppl.): 1999.
8. Halushka, PV and **Oates, JC**. Peripheral Arterial Thrombosis and Selective Inhibition of COX-2: Who is at risk? Invited presentation for the Third International COX-2 Workshop, 1999.
9. Reilly CM, **Oates JC**, Gilkeson GS. PGJ₂ inhibition of mesangial cells iNOS expression. 11th Int. Conf Advances in Prostaglandin and Leukotriene Research, Florence, Italy, 2000.
10. **Oates JC**, Farrelly L, Gilkeson GS. Nitric oxide induces apoptosis in lupus peripheral blood mononuclear cells. *Arthritis Rheum.* 43(suppl.): 2000.
11. Taylor JG, Farrelly L, **Oates JC**. Increased systemic nitric oxide (NO) production in a murine model of systemic sclerosis (SSc). *Arthritis Rheum.* 43(suppl.): 1999.
12. **Oates JC**, Farrelly LW, Hofbauer AF, Hensley K, Durazo-Arvizu RA, Gilkeson GS. Systemic nitric oxide production is associated with apoptosis of lupus peripheral blood mononuclear cells. *Arthritis Rheum.* 45(suppl.): 2002.
13. Njoku CJ, Gilkeson GS, Morrow JD, Ruiz P, and **Oates JC**. Effect of inducible nitric oxide synthase inhibitors on eicosanoid metabolism in murine lupus nephritis. *J Invest Med* 51(suppl 1):S281:2003.
14. Oates JC, Gilkeson GS. Role of nitric oxide in MRL/*lpr* splenocyte apoptosis: a possible PKC-mediated mechanism. In: *Annual European Congress of Rheumatology; 2003; Lisbon, Portugal; 2003.*
15. Afrin LB, **Oates JC**, Daniels MS. Leveraging of Open EMR Architecture for Clinical Trial Accrual. In: *American Medical Informatics Association Symposium; Washington, DC; 2003.*
16. **Oates JC**, Morrow JD, Shaftman SR, Gilkeson GS. Renal eicosanoid production in lupus nephritis: Association with disease activity and prednisone use. *American College of Rheumatology National Meeting, San Antonio, TX 2004.*
17. **Oates JC**, Njoku CJ, Patrick KS. Pharmacologic inhibition of inducible nitric oxide synthase reduces systemic oxidant stress in murine proliferative nephritis. In: *Free Radical Biology & Medicine 11th Annual Meeting; 2004; St. Thomas, USVI: Elsevier; 2004. p. S137.*
18. Kamen DL, Barron M, Hollis BW, **Oates JC**, Bouali H, Bruner GR, Harle, JB, Gilkeson GS.

- Correlation of vitamin D deficiency with lupus disease measures among Sea Island Gullah African Americans. American College of Rheumatology National Meeting, San Diego, CA 2005.
19. **Oates JC**, Njoku CJ, Patrick, KS, Ruiz, P, Gilkeson GS. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. American College of Rheumatology National Meeting, San Diego, CA 2005.
 20. Caldwell RD, Fleury TW, Salmon JE, Roman MJ, and **Oates JC**. Modifications of tyrosine as biomarkers of atherosclerosis in systemic lupus erythematosus. Southern Regional Meeting, Atlanta, GA March 2006.
 21. Njoku CJ, Patrick KS, and **Oates JC**. Urine F2-isoprostanes are reduced in lupus nephritis. Southern Regional Meeting, Atlanta, GA March 2006.
 22. **Oates JC**, Gilkeson GS. Serum nitrate and nitrite levels are greater in systemic lupus erythematosus and lupus nephritis in association with disease activity. Fourth International Conference of the Nitric Oxide Society on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide. Monterey, CA June 25-29, 2006.
 23. **Oates JC**, Shaftman SR, Hofbauer AE, Gilkeson GS. Serum Nitrate + Nitrite Associates with Lupus, Lupus Nephritis, and Lupus Disease Activity Markers in a Longitudinal Analysis. American College of Rheumatology National Meeting, November 11-15, 2006, Washington DC. Oral presentation.
 24. **Oates JC**, Shaftman SR, Bird-Lake K, Gilkeson GS, Self SE. Predictors of Outcome Among Clinical and Biopsy Variables in Lupus Nephritis. American College of Rheumatology National Meeting, November 11-15, 2006, Washington DC. Poster presentation number 254.
 25. Njoku CJ, Gilkeson GS, Hofbauer AE, Ruiz P, **Oates JC**. The Response of MRL/lpr –inducible nitric oxide synthase knockout mice to an inducible nitric oxide synthase inhibitor. Southern Regional Meeting, Feb 8-10, 2007. New Orleans, LA. Oral presentation abstract 191.
 26. **Oates JC**, Njoku CJ, Gilkeson GS, Hofbauer AF, Ruiz P. Response to inducible nitric oxide synthase inhibitor in a murine lupus model deficient in the inducible nitric oxide synthase gene. Lupus International Congress, May 22 – 26, 2007. Shanghai, China. Oral presentation.
 27. Merrill JC, Neuwelt M, Wallace D, Shanahan J, Latinis K, **Oates J**, Utset T, Gordon C, Isenberg D, Zhang D, Brunetta P. Design and baseline characteristics of patients in a randomized double-blind, placebo-controlled phase II/III study (EXPLORER) to evaluate the efficacy and safety of rituximab in patients with moderate to severely active systemic lupus erythematosus (SLE). European League Against Rheumatism, June 13, 2008. Paris, France. Poster 1180.
 28. **Oates JC**, Hofbauer AF, EuDaly J, Smith CD.. Pharmacologic Sphingosine Kinase-1 Inhibition with ABC94640 Prevents Proteinuria and Improves Survival In the Mrl/lpr Murine Model of Lupus. American College of Rheumatology National Meeting, October 26, 2008. San Francisco, CA. Poster presentation number 390.
 29. Beall AD, Nietert PD, Lake KS, Gilkeson GS, **Oates JC**, Kamen DL. Long Term Outcomes and Therapeutic Trends among Patients with Lupus Nephritis. American College of Rheumatology National Meeting, October 27, 2008. San Francisco, CA. Poster presentation number F97.
 30. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, **Oates JC**, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and Safety of Rituximab in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (SLE): Results from the Randomized, Double-blind Phase II/III Study EXPLORER. American College of Rheumatology National Meeting, October 27, 2008. San Francisco, CA. Oral presentation Oct 28, 2008.
 31. Richard M, **Oates JC**, Silver RM, Hoffman S, Tourkina E. Caveolin-1 Regulates Normal and Scleroderma Leukocyte Functions American College of Rheumatology National Meeting, October 29, 2008. San Francisco, CA. Oral Presentation.
 32. Soodavar F, Heller D, Hofbauer AF, Oates JC, Hammad SM. Sphingolipids and Accelerated Heart Disease in Lupus. South East Lipid Research Conference (SELRC), October 2-5, 2008. Pine Mountain, Georgia.
 33. Ravennel R, Fleury TW, Donohue J, Shaftman SR, Oates JC. Biomarkers of Atherosclerosis in Systemic Lupus Erythematosus. Southern Regional Meeting, Feb 12-14, 2007\9. New Orleans, LA. Oral presentation abstract 249.
 34. Mashmouhi AK, Hofbauer AF, Gilkeson GS, Oates JC. Role of Reactive Intermediates in Lupus Nephritis. Southern Regional Meeting, Feb 12-14, 2007\9. New Orleans, LA. Oral presentation abstract 249.